Our group described the association of oncomiR‐155 with the BCR‐activated phenotype in CLL, its upregulation correlating with shorter patient survival, and its downmodulation following therapy with the BCR‐targeted agent ibrutinib 6. Here, BCR is linked to B-cell chronic lymphocytic leukemia.